Emily C. Ayers

718 total citations
19 papers, 69 citations indexed

About

Emily C. Ayers is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Emily C. Ayers has authored 19 papers receiving a total of 69 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 10 papers in Genetics and 9 papers in Oncology. Recurrent topics in Emily C. Ayers's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Emily C. Ayers is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Emily C. Ayers collaborates with scholars based in United States, Italy and Canada. Emily C. Ayers's co-authors include Steven M. Bair, Joshua D. Brandstadter, Edward A. Stadtmauer, Anthony R. Mato, Daniel J. Landsburg, David M. Margolis, Craig A. Portell, David J. Margolis, Phyllis A. Gimotty and Rawan Faramand and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Emily C. Ayers

15 papers receiving 68 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emily C. Ayers United States 5 35 33 17 13 12 19 69
Stephanie Mueller Germany 4 39 1.1× 48 1.5× 7 0.4× 12 0.9× 10 0.8× 8 88
Will Donnellan United States 4 37 1.1× 46 1.4× 14 0.8× 7 0.5× 19 1.6× 6 73
Louise Roulin France 6 47 1.3× 36 1.1× 28 1.6× 9 0.7× 14 1.2× 18 90
Carlos Litovich United States 6 80 2.3× 65 2.0× 15 0.9× 18 1.4× 15 1.3× 12 99
Jaap A. van Doesum Netherlands 6 46 1.3× 23 0.7× 5 0.3× 10 0.8× 6 0.5× 11 63
Danielle Leão Cordeiro de Farias Brazil 6 35 1.0× 33 1.0× 40 2.4× 12 0.9× 17 1.4× 15 93
Zhiming Li China 7 40 1.1× 65 2.0× 22 1.3× 27 2.1× 6 0.5× 12 87
H Schouten Netherlands 5 53 1.5× 38 1.2× 23 1.4× 11 0.8× 22 1.8× 6 81
Jérôme Paillassa France 6 38 1.1× 37 1.1× 35 2.1× 23 1.8× 10 0.8× 20 78
Sigrid Kolders Netherlands 2 30 0.9× 25 0.8× 6 0.4× 7 0.5× 6 0.5× 3 69

Countries citing papers authored by Emily C. Ayers

Since Specialization
Citations

This map shows the geographic impact of Emily C. Ayers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily C. Ayers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily C. Ayers more than expected).

Fields of papers citing papers by Emily C. Ayers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily C. Ayers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily C. Ayers. The network helps show where Emily C. Ayers may publish in the future.

Co-authorship network of co-authors of Emily C. Ayers

This figure shows the co-authorship network connecting the top 25 collaborators of Emily C. Ayers. A scholar is included among the top collaborators of Emily C. Ayers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily C. Ayers. Emily C. Ayers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Ayers, Emily C. & Sonali M. Smith. (2025). Diffuse Large B-Cell Lymphoma in the Older and Frail Patient. Cancers. 17(5). 885–885.
3.
Epperla, Narendranath, Adam J. Olszewski, Emily C. Ayers, & Sairah Ahmed. (2025). Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma. Hematological Oncology. 43(5). e70128–e70128. 1 indexed citations
4.
Alderuccio, Juan Pablo, Craig Okada, Emily C. Ayers, et al.. (2025). 78 | INITIAL RESULTS FROM LOTIS‐7: A PHASE 1B STUDY OF LONCASTUXIMAB TESIRINE PLUS GLOFITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematological Oncology. 43(S3). 2 indexed citations
5.
Alderuccio, Juan Pablo, Craig Okada, Emily C. Ayers, et al.. (2025). ABCL-777: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma Myeloma & Leukemia. 25. S758–S758. 1 indexed citations
6.
7.
Roberts, Nathan, Ifeyinwa E. Obiorah, Prem P. Batchala, & Emily C. Ayers. (2024). Follicular Lymphoma with Cranial Nerve and Central Nervous System Involvement Successfully Treated with Bendamustine and Rituximab: A Case Report and Literature Review. Medical Research Archives. 12(5).
8.
Ayers, Emily C., Julien Depaus, Fritz Offner, et al.. (2024). ABCL-353 Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7). Clinical Lymphoma Myeloma & Leukemia. 24. S474–S474. 1 indexed citations
9.
Portell, Craig A., et al.. (2023). Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?. Blood Reviews. 61. 101101–101101. 6 indexed citations
10.
11.
Ayers, Emily C., Jeffrey M. Wilson, Glenda Canderan, et al.. (2021). Antibody and T-Cell Responses to Covid-19 mRNA Vaccines in Patients with B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CLL). Blood. 138(Supplement 1). 1335–1335. 1 indexed citations
12.
Ayers, Emily C., David M. Margolis, & Daniel J. Landsburg. (2020). Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. Clinical Lymphoma Myeloma & Leukemia. 20(10). 661–667. 8 indexed citations
13.
Bair, Steven M., Joshua D. Brandstadter, Emily C. Ayers, & Edward A. Stadtmauer. (2020). Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer. 126(9). 1837–1855. 23 indexed citations
14.
Behdad, Amir, Angela J. Fought, Timothy Taxter, et al.. (2019). Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. Leukemia & lymphoma. 60(13). 3266–3271. 1 indexed citations
15.
Ayers, Emily C., David J. Margolis, Phyllis A. Gimotty, & Daniel J. Landsburg. (2019). Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy. Blood. 134(Supplement_1). 2893–2893. 2 indexed citations
16.
Nasta, Sunita D., Stephen J. Schuster, Jakub Svoboda, et al.. (2019). Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement. Blood. 134(Supplement_1). 1607–1607. 2 indexed citations
17.
Landsburg, Daniel J., Emily C. Ayers, David A. Bond, et al.. (2019). Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy. British Journal of Haematology. 189(2). 313–317. 7 indexed citations
18.
Ayers, Emily C., et al.. (2016). Personalized Management Approaches in Lymphoma. PET Clinics. 11(3). 209–218. 1 indexed citations
19.
Ayers, Emily C. & Anthony R. Mato. (2016). Richter's Transformation in the Era of Kinase Inhibitor Therapy: A Review. Clinical Lymphoma Myeloma & Leukemia. 17(1). 1–6. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephanie Mueller Breakdown of academic impact, for papers by Will Donnellan Breakdown of academic impact, for papers by Louise Roulin Breakdown of academic impact, for papers by Carlos Litovich Breakdown of academic impact, for papers by Jaap A. van Doesum Breakdown of academic impact, for papers by Danielle Leão Cordeiro de Farias Breakdown of academic impact, for papers by Zhiming Li Breakdown of academic impact, for papers by H Schouten Breakdown of academic impact, for papers by Jérôme Paillassa Breakdown of academic impact, for papers by Sigrid Kolders
Rankless by CCL
2026